Acarbose, an α-glucosidase inhibitor, improves insulin resistance in fructose-fed rats

K. Nakamura, Sho Ichi Yamagishi, T. Matsui, Hiroyoshi Inoue

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Insulin resistance is one of the determinants of postprandial hyperglycemia. Acarbose is an α-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, thereby suppressing postprandial hyperglycemia. Recently, acarbose has been found to reduce the incidence of cardiovascular disease (CVD) in patients with diabetes. These observations suggest that intervention of postprandial hyperglycemia with acarbose is a promising strategy for the prevention of CVD in diabetic patients. However, the effects of acarbose on insulin sensitivity are not fully understood. In this study, we examined whether oral administration of acarbose could improve insulin sensitivity in fructose-fed rats, a widely used insulin-resistant animal model. Although plasma glucose levels remained unchanged during the experiments, serum insulin levels were significantly increased in fructose-fed rats, which were suppressed by 4 weeks of treatment with acarbose. Acarbose treatment also increased high-density lipoprotein levels in fructose-fed rats. Furthermore, treatment of acarbose inhibited the elevation of systolic blood pressure levels in fructose-fed rats. These results indicate that oral administration of acarbose improves insulin sensitivity in fructose-fed rats. Our present study suggests that the cardioprotecive effects of acarbose could be ascribed, at least in part, to its insulin-sensitizing property.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalDrugs under Experimental and Clinical Research
Volume31
Issue number4
Publication statusPublished - 2005
Externally publishedYes

Fingerprint

Acarbose
Glucosidases
Fructose
Insulin Resistance
Hyperglycemia
Insulin
Oral Administration
Cardiovascular Diseases
Blood Pressure
HDL Lipoproteins
Small Intestine
Therapeutics
Animal Models
Carbohydrates

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology
  • Drug Discovery

Cite this

Acarbose, an α-glucosidase inhibitor, improves insulin resistance in fructose-fed rats. / Nakamura, K.; Yamagishi, Sho Ichi; Matsui, T.; Inoue, Hiroyoshi.

In: Drugs under Experimental and Clinical Research, Vol. 31, No. 4, 2005, p. 155-159.

Research output: Contribution to journalArticle

@article{7fa50d4f7c014bfabc733cd9f4bee546,
title = "Acarbose, an α-glucosidase inhibitor, improves insulin resistance in fructose-fed rats",
abstract = "Insulin resistance is one of the determinants of postprandial hyperglycemia. Acarbose is an α-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, thereby suppressing postprandial hyperglycemia. Recently, acarbose has been found to reduce the incidence of cardiovascular disease (CVD) in patients with diabetes. These observations suggest that intervention of postprandial hyperglycemia with acarbose is a promising strategy for the prevention of CVD in diabetic patients. However, the effects of acarbose on insulin sensitivity are not fully understood. In this study, we examined whether oral administration of acarbose could improve insulin sensitivity in fructose-fed rats, a widely used insulin-resistant animal model. Although plasma glucose levels remained unchanged during the experiments, serum insulin levels were significantly increased in fructose-fed rats, which were suppressed by 4 weeks of treatment with acarbose. Acarbose treatment also increased high-density lipoprotein levels in fructose-fed rats. Furthermore, treatment of acarbose inhibited the elevation of systolic blood pressure levels in fructose-fed rats. These results indicate that oral administration of acarbose improves insulin sensitivity in fructose-fed rats. Our present study suggests that the cardioprotecive effects of acarbose could be ascribed, at least in part, to its insulin-sensitizing property.",
author = "K. Nakamura and Yamagishi, {Sho Ichi} and T. Matsui and Hiroyoshi Inoue",
year = "2005",
language = "English",
volume = "31",
pages = "155--159",
journal = "Drugs under Experimental and Clinical Research",
issn = "0378-6501",
publisher = "Bioscience Ediprint Inc.",
number = "4",

}

TY - JOUR

T1 - Acarbose, an α-glucosidase inhibitor, improves insulin resistance in fructose-fed rats

AU - Nakamura, K.

AU - Yamagishi, Sho Ichi

AU - Matsui, T.

AU - Inoue, Hiroyoshi

PY - 2005

Y1 - 2005

N2 - Insulin resistance is one of the determinants of postprandial hyperglycemia. Acarbose is an α-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, thereby suppressing postprandial hyperglycemia. Recently, acarbose has been found to reduce the incidence of cardiovascular disease (CVD) in patients with diabetes. These observations suggest that intervention of postprandial hyperglycemia with acarbose is a promising strategy for the prevention of CVD in diabetic patients. However, the effects of acarbose on insulin sensitivity are not fully understood. In this study, we examined whether oral administration of acarbose could improve insulin sensitivity in fructose-fed rats, a widely used insulin-resistant animal model. Although plasma glucose levels remained unchanged during the experiments, serum insulin levels were significantly increased in fructose-fed rats, which were suppressed by 4 weeks of treatment with acarbose. Acarbose treatment also increased high-density lipoprotein levels in fructose-fed rats. Furthermore, treatment of acarbose inhibited the elevation of systolic blood pressure levels in fructose-fed rats. These results indicate that oral administration of acarbose improves insulin sensitivity in fructose-fed rats. Our present study suggests that the cardioprotecive effects of acarbose could be ascribed, at least in part, to its insulin-sensitizing property.

AB - Insulin resistance is one of the determinants of postprandial hyperglycemia. Acarbose is an α-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, thereby suppressing postprandial hyperglycemia. Recently, acarbose has been found to reduce the incidence of cardiovascular disease (CVD) in patients with diabetes. These observations suggest that intervention of postprandial hyperglycemia with acarbose is a promising strategy for the prevention of CVD in diabetic patients. However, the effects of acarbose on insulin sensitivity are not fully understood. In this study, we examined whether oral administration of acarbose could improve insulin sensitivity in fructose-fed rats, a widely used insulin-resistant animal model. Although plasma glucose levels remained unchanged during the experiments, serum insulin levels were significantly increased in fructose-fed rats, which were suppressed by 4 weeks of treatment with acarbose. Acarbose treatment also increased high-density lipoprotein levels in fructose-fed rats. Furthermore, treatment of acarbose inhibited the elevation of systolic blood pressure levels in fructose-fed rats. These results indicate that oral administration of acarbose improves insulin sensitivity in fructose-fed rats. Our present study suggests that the cardioprotecive effects of acarbose could be ascribed, at least in part, to its insulin-sensitizing property.

UR - http://www.scopus.com/inward/record.url?scp=26244468723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244468723&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 155

EP - 159

JO - Drugs under Experimental and Clinical Research

JF - Drugs under Experimental and Clinical Research

SN - 0378-6501

IS - 4

ER -